Harigae H. XLSA breakthrough: gene therapy potential. Blood. 2025 Jan 2;145(1):5-6. doi: 10.1182/blood.2024026582. PMID: 39745690 No abstract available. https://pubmed.ncbi.nlm.nih.gov/39745690/
Kubo R, Onodera K, Onishi Y, Fukuhara N, Harigae H. Long-term remission following CAR-T therapy in a patient with transformed follicular lymphoma relapse after allogeneic stem cell transplantation. Ann Hematol. 2025 Jan;104(1):841-845. doi: 10.1007/s00277-024-06150-8. Epub 2024 Dec 30. PMID: 39738826 https://pubmed.ncbi.nlm.nih.gov/39738826/
Kosugi H, Fujisaki T, Iwasaki H, Shinagawa A, Iida H, Jo T, Kubonishi S, Morita Y, Nakashima Y, Onodera K, Suzuki K, Suzuki T, Tamai Y, Usuki K, Yokota A, Yonaga H, Hayakawa J, Midorikawa S, Nishio M, Suda M, Matsue K. A phase 2 clinical trial of luspatercept in non-transfusion-dependent patients with myelodysplastic syndromes. Int J Hematol. 2025 Jan;121(1):68-78. doi: 10.1007/s12185-024-03872-3. Epub 2024 Nov 21. PMID: 39572468 Free PMC article. Clinical Trial. https://pubmed.ncbi.nlm.nih.gov/39572468/
Shimada K, Yamaguchi M, Kuwatsuka Y, Matsue K, Sato K, Kusumoto S, Nagai H, Takizawa J, Fukuhara N, Nagafuji K, Miyazaki K, Ohtsuka E, Okamoto A, Sugita Y, Uchida T, Kayukawa S, Wake A, Ennishi D, Kondo Y, Meguro A, Kin Y, Minami Y, Hashimoto D, Nishiyama T, Shimada S, Masaki Y, Okamoto M, Atsuta Y, Kiyoi H, Suzuki R, Nakamura S, Kinoshita T. Rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone combined with high-dose methotrexate plus intrathecal chemotherapy for newly diagnosed intravascular large B-cell lymphoma (PRIMEUR-IVL): long-term results of a multicentre, single-arm, phase 2 trial. EClinicalMedicine. 2025 Jan 31;80:103078. doi: 10.1016/j.eclinm.2025.103078. eCollection 2025 Feb. PMID: 39968389 Free PMC article. https://pubmed.ncbi.nlm.nih.gov/39968389/
Okada Y, Tachi N, Shimazu Y, Murata M, Nishiwaki S, Onishi Y, Jinguji A, Uchida N, Tanaka M, Hasegawa Y, Ito A, Kako S, Nishida T, Onodera K, Sawa M, Nakamae H, Toyosaki M, Kanda Y, Onizuka M, Fukuda T, Ohbiki M, Atsuta Y, Arai Y, Tachibana T. Comparing de novo chronic myeloid leukemia in blastic phase with Philadelphia chromosome-positive acute lymphoblastic leukemia after allogeneic hematopoietic cell transplantation. Cancer. 2025 Jan 1;131(1):e35627. doi: 10.1002/cncr.35627. Epub 2024 Nov 4. PMID: 39497254 https://pubmed.ncbi.nlm.nih.gov/39497254/
Munakata W, Kumode T, Goto H, Fukuhara N, Shimoyama T, Takeuchi M, Kawakita T, Kubo K, Sawa M, Uchida T, Mishima Y, Ichii M, Hanaya M, Matsumoto A, Kuriki M, Seike T, Izutsu K, Ishizawa K. A phase II study of zandelisib in patients with relapsed or refractory indolent non-Hodgkin lymphoma: ME-401-K02 study. Br J Haematol. 2025 Feb;206(2):541-550. doi: 10.1111/bjh.19994. Epub 2025 Jan 8. PMID: 39778876 Free PMC article. Clinical Trial. https://pubmed.ncbi.nlm.nih.gov/39778876/
Nato Y, Miyazaki K, Maruyama D, Takahashi H, Sunami K, Murakami S, Negoro E, Miyazawa Y, Choi I, Okada T, Takayama N, Tomita N, Momose S, Kaneda Y, Yoshida M, Gomyo H, Toyama K, Nishikori M, Saito A, Hiraga J, Masunari T, Takahashi N, Makiyama J, Suzuki T, Tsunemine H, Takizawa J, Kato T, Masaki Y, Fukuhara N, Okamoto M, Tawara I, Asano N, Ohshima K, Izutsu K, Kato K, Suzuki R, Yamaguchi M. Treatments and Outcomes of Newly Diagnosed CD5-Positive Diffuse Large B-Cell Lymphoma: A Multi-Institutional Observational Study. Hematol Oncol. 2025 Mar;43(2):e70047. doi: 10.1002/hon.70047. https://pubmed.ncbi.nlm.nih.gov/39937961/
Fujimoto A, Miyazaki K, Yakushijin K, Fujino T, Munakata W, Ejima Y, Maruyama D, Kubota N, Maeda T, Takizawa J, Hiramoto N, Takeuchi M, Sakai R, Fukuhara N, Taguchi S, Asano N, Yamaguchi M, Suzuki R. Improved prognosis of advanced-stage extranodal NK/T-cell lymphoma: results of the NKEA-Next study. Leukemia. 2025 Apr;39(4):909-916. doi: 10.1038/s41375-025-02527-4. Epub 2025 Feb 17. PMID: 39962328 https://pubmed.ncbi.nlm.nih.gov/39962328/
Takahashi N, Harigae H. PAI-1, hematopoietic stem cell, and chronic myeloid leukemia. Biomed J. 2025 Apr 18:100854. doi: 10.1016/j.bj.2025.100854. Online ahead of print. PMID: 40254273 Free article. https://pubmed.ncbi.nlm.nih.gov/40254273/
Izutsu K, Fukuhara N. JSH practical guidelines for hematological malignancies, 2023: II. Lymphoma-1. Follicular lymphoma (FL). Int J Hematol. 2025 May;121(5):577-585. doi: 10.1007/s12185-025-03922-4. Epub 2025 Feb 4. PMID: 39903435 No abstract available. https://pubmed.ncbi.nlm.nih.gov/39903435/
Fukuhara N, Yoshida I, Ishiguro T, Fujimoto K, Kuroda J, Uchida T, Yamamoto R, Ogawa Y, Hiramatsu Y, Ito T, Katagiri S, Nakazato T, Suzukawa K, Kinami K, Zhou M, Negoro E. PI3Kδ Inhibitor Parsaclisib in Japanese Patients With Relapsed or Refractory Follicular Lymphoma. Cancer Sci. 2025 Aug;116(8):2189-2197. doi: 10.1111/cas.70046. Epub 2025 May 14. PMID: 40365847 Free article. https://pubmed.ncbi.nlm.nih.gov/40365847/
Izutsu K, Kumode T, Yuda J, Nagai H, Mishima Y, Suehiro Y, Yamamoto K, Fujisaki T, Ishitsuka K, Ishizawa K, Ikezoe T, Nishikori M, Akahane D, Fujita J, Jafarinasabian P, Soong D, D'Angelo Månsson B, Takahashi A, Favaro E, Fukuhara N. Efficacy and safety of epcoritamab in Japanese patients with relapsed or refractory diffuse large B-cell lymphoma: 3-year follow-up from the EPCORE NHL-3 trial. Int J Clin Oncol. 2025 Aug;30(8):1631-1640. doi: 10.1007/s10147-025-02788-0. Epub 2025 May 28. PMID: 40434509 https://pubmed.ncbi.nlm.nih.gov/40434509/
Kobayashi T, Ishizawa K, Machida R, Sadachi R, Sasaki K, Kim H, Kataoka K, Munakata W, Fukuhara N, Nagai H; Lymphoma Study Group of the Japan Clinical Oncology Group. Obinutuzumab maintenance versus observation for patients with newly diagnosed high tumor burden follicular lymphoma who achieved complete metabolic response after obinutuzumab plus bendamustine induction therapy: a multicenter, randomized, phase III study (JCOG2008, MAIN study). Jpn J Clin Oncol. 2025 Jun 5;55(6):666-671. doi: 10.1093/jjco/hyaf038. PMID: 39997358 https://pubmed.ncbi.nlm.nih.gov/39997358/
Fukuhara N, Onizuka M, Kanda J, Asada N, Kato K, Ando K. Protocol for a multicentre, open-label, dose-escalation phase I/II study evaluating the tolerability, safety, efficacy and pharmacokinetics of repeated continuous intravenous PPMX-T003 in patients with aggressive natural killer cell leukaemia. BMJ Open. 2025 Jun 30;15(6):e098532. doi: 10.1136/bmjopen-2024-098532. PMID: 40588385 Free PMC article. https://pubmed.ncbi.nlm.nih.gov/40588385/
Watanabe S, Kato H, Fujiwara T, Hatta S, Tomiya Y, Onodera K, Ichikawa S, Onishi Y, Yokoyama H, Fujishima F, Ichinohasama R, Harigae H, Fukuhara N. High FCGR2B Expression Can Identify Low-tumor-burden Follicular Lymphoma Patients Who Do Not Require Any Antilymphoma Therapy for a Long Term. Am J Surg Pathol. 2025 Jul 1;49(7):740-747. doi: 10.1097/PAS.0000000000002397. Epub 2025 Apr 7. PMID: 40191878 https://pubmed.ncbi.nlm.nih.gov/40191878/
Fujiwara T, Harigae H. Molecular Insights into the Pathophysiology of Dysregulated Erythropoiesis: The Crucial Role of Iron Homeostasis. Mol Cell Biol. 2025 Sep 10:1-14. doi: 10.1080/10985549.2025.2553648. Online ahead of print. PMID: 40928051 https://pubmed.ncbi.nlm.nih.gov/40928051/
Ohmachi K, Kinoshita T, Maruyama D, Machida R, Sano Y, Yamauchi N, Fukuhara N, Uchida T, Yamamoto K, Miyazaki K, Tsukamoto N, Iida S, Yoshida I, Imaizumi Y, Suzuki Y, Yoshida S, Masaki Y, Murayama T, Yakushijin Y, Suehiro Y, Nosaka K, Dobashi N, Kuroda J, Takamatsu Y, Munakata W, Ando K, Ishizawa K, Ogura M, Yoshino T, Hotta T, Tsukasaki K, Tobinai K, Nagai H. Final results of JCOG0601 randomized trial of R-CHOP versus CHOP combined with dose-dense rituximab for diffuse large B-cell lymphoma. Jpn J Clin Oncol. 2025 Sep 2:hyaf134. doi: 10.1093/jjco/hyaf134. Online ahead of print. PMID: 40891733 https://pubmed.ncbi.nlm.nih.gov/40891733/
Goto H, Ito S, Kizaki M, Yamaguchi M, Fukuhara N, Kato K, Saito T, Terui Y, Soshin T, Satomi-Tsushita N, Honda H, Qian C, Izutsu K. Long-term outcomes of venetoclax and ibrutinib in Japanese patients with relapsed/refractory mantle cell lymphoma. Int J Clin Oncol. 2025 Sep 2. doi: 10.1007/s10147-025-02865-4. Online ahead of print. PMID: 40897939 https://pubmed.ncbi.nlm.nih.gov/40897939/
Mishima Y, Hashimoto D, Ichii M, Fukuhara N, Uchida T, Kato K, Omi A, Koroki Y, Shiga K, Maruyama D. Impact of best response to ibrutinib plus Bendamustine and rituximab on PFS in MCL: a secondary analysis of SHINE. Ann Hematol. 2025 Sep 13. doi: 10.1007/s00277-025-06569-7. Online ahead of print. PMID: 40940567 https://pubmed.ncbi.nlm.nih.gov/40940567/
Izutsu K, Akahane D, Toubai T, Saito T, Mishima Y, Fujisaki T, Nishikori M, Kumode T, Suehiro Y, Ishitsuka K, Conlon R, Takahashi A, D'Angelo Månsson B, Favaro E, Fukuhara N. Subcutaneous epcoritamab monotherapy in Japanese patients with relapsed or refractory follicular lymphoma: primary results of the EPCORE NHL-3 trial. Leuk Lymphoma. 2025 Oct;66(10):1913-1921. doi: 10.1080/10428194.2025.2525983. Epub 2025 Jul 9. PMID: 40632620 https://pubmed.ncbi.nlm.nih.gov/40632620/
Saburi M, Masunari T, Fukuhara N, Inagaki Y, Shimura A, Imoto N, Hasegawa Y, Hagihara M, Kobayashi N, Kumekawa H, Nakazawa H, Miyazaki K, Kawakita T, Isshiki T, Katsube A, Fujisawa S, Horigome Y, Koba Y, Jinnouchi F, Sekiguchi N. The Impact of Tirabrutinib Monotherapy for the Treatment of Bing-Neel Syndrome: A Multicenter Retrospective Study. Am J Hematol. 2025 Oct;100(10):1912-1915. doi: 10.1002/ajh.70029. Epub 2025 Aug 2. PMID: 40751704 https://pubmed.ncbi.nlm.nih.gov/40751704/
Yokoyama H, Fukuhara N, Ando K, Iida H, Yamauchi T, Fukuhara S, Izutsu K, Tanoue Y, Yamamoto M, Tozaki H, Takahara E, Shoji S, Mizutani A, Morishita D, Oda RW, Miyake H, Yamamoto N. Phase I Study of Rogocekib in Patients with Relapsed or Refractory Hematologic Malignancies. Blood Adv. 2025 Oct 7:bloodadvances.2025017601. doi:10.1182/bloodadvances.2025017601. Online ahead of print. PMID: 41056522 https://pubmed.ncbi.nlm.nih.gov/41056522/
Zaimoku Y, Yamazaki H, Kanaya M, Hiramoto N, Ishiyama K, Takenaka K, Murata M, Uchida N, Doki N, Yamamoto R, Nishida T, Onodera K, Machida S, Kanda Y, Eto T, Kataoka K, Asada N, Itagaki M, Sakata-Yanagimoto M, Ishimaru F, Onizuka M, Ichinohe T, Atsuta Y, Onishi Y. Loss-Prone HLA Class I Alleles Inform Outcomes of Early Hematopoietic Cell Transplantation in Acquired Aplastic Anemia. Am J Hematol. 2025 Sep 5. doi: 10.1002/ajh.70054. Online ahead of print. PMID: 40910546 https://pubmed.ncbi.nlm.nih.gov/40910546/
Sakurai M, Kataoka K, Mizuno K, Mori T, Shirane S, Sakaguchi H, Mori T, Tanaka M, Tokunaga M, Onizuka M, Sakata-Yanagimoto M, Ishikawa J, Katayama Y, Ota S, Sawa M, Kato J, Hasegawa Y, Onodera K, Hattori N, Miyakoshi S, Takayama N, Nishida T, Kato K, Ishimaru F, Atsuta Y, Kanda J, Nakasone H, Terakura S. Risk Factors for and Impact of Pre-Engraftment Syndrome on Outcomes Following Single-Unit Cord Blood Transplantation in Adults. Am J Hematol. 2025 Sep 26. doi: 10.1002/ajh.70094. Online ahead of print. PMID: 41002003 https://pubmed.ncbi.nlm.nih.gov/41002003/